The role of FLT3/ITD mutations as a MRD marker is controversial because it is considered as a relatively unstable marker that may lost at relapse.   2  The high level of WT1 expression in BM and PB is associated with the presence of disease in AML patients and increase in WT1 levels before hematological relapse can be showing its role in MRD monitoring.   2  But, WT1 expression in normal PB and BM cells leads to low sensitivity of MRD analysis in AML patients.   9. Here, WT1 is linked to acute myeloid leukemia.